Argus
•
Apr 29, 2026
ARWR: Lowering target price to $74.00
Summary
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, charac
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Alnylam Pharmaceuticals, Inc.
May 01, 2026
•
ALNY
Analyst Report: Merck & Co., Inc.
May 01, 2026
•
MRK
Analyst Report: Ionis Pharmaceuticals, Inc.
Apr 30, 2026
•
IONS
Analyst Report: Ionis Pharmaceuticals, Inc.
Apr 30, 2026
•
IONS
TGTX: Lowering target price to $36.00
Apr 29, 2026
•
TGTX
